Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316315 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma
A Phase 1 study, sponsored by Nivalis Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01316315 is a Phase 1 study that has completed, run by Nivalis Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT01316315, a Phase 1 study, has completed, sponsored by Nivalis Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a single IV dose of N6022 will have a significant bronchoprotective effect, compared with placebo, during methacholine challenge.
Interventions
- DRUG Placebo
- DRUG Active
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01316315
The ClinicalTrials.gov registry entry for NCT01316315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nivalis Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01316315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01316315 about?
NCT01316315 is a clinical study titled "Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma". The purpose of this study is to determine whether a single IV dose of N6022 will have a significant bronchoprotective effect, compared with placebo, during methacholine challenge.
What is the current status of trial NCT01316315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01316315?
The interventions under investigation include: Placebo (DRUG), Active (DRUG).
Who is sponsoring clinical trial NCT01316315?
This trial is sponsored by Nivalis Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.